Medartis Holding AG (MED) AI Stock Analysis

• Market Cap: CHF1.09B
• Dividend Yield: N/A
• Average Volume (3M): 6.38K
• Price to Earnings (P/E): 131.1
• Beta (1Y): 0.92
• Revenue Growth: 7.29%
• EPS Growth: -112.70%
• Country: CH
• Employees: 816
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.79
• Shares Outstanding: 13,632,277
• 10 Day Avg. Volume: 7,172
• 30 Day Avg. Volume: 6,381
• PEG Ratio: 0.94
• Price to Book (P/B): 3.97
• Price to Sales (P/S): 4.07
• P/FCF Ratio: 117.19
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: CHF87.00
• Price Target Upside: -1.36% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 1
• EPS Forecast (FY): 1.53
• Revenue Forecast (FY): CHF328.12M

• Rating: 51 Neutral
• Price Target: CHF79.00 ▼(-10.43% Downside)
• Action: Reiterated Date: 03/23/26
• Date: Action: Reiterated 03/23/26

The score is held back primarily by uneven profitability alongside rising leverage and weaker 2025 free cash flow, despite solid revenue growth and improving operating cash flow. Technical indicators also remain bearish with the stock trading below major moving averages. Valuation is a further headwind due to a negative P/E and no dividend support.

Positive Factors

Focused, procedure-driven business model

Medartis’s focused product portfolio (plates, screws, instruments) for cranio‑maxillofacial and hand/upper‑extremity procedures creates durable, procedure‑driven demand. System sales plus instrument placement and surgeon training tend to drive repeat implant usage and steady revenue streams over time.

Negative Factors

Materially rising leverage

A sharp increase in debt materially raises financial risk and reduces strategic flexibility. With leverage elevated, interest burdens and covenant risk could constrain capital allocation, limit M&A or R&D pacing, and amplify earnings volatility if cash generation weakens.

Medartis Holding AG Business Overview & Revenue Model

Company Description

Medartis Holding AG, a medical device company, develops, manufactures, and sells implant solutions worldwide. Its medical devices are used for the treatment of surgical fixation of bone fractures for upper and lower extremities, as well as for the...

Read more

Medartis Holding AG, a medical device company, develops, manufactures, and sells implant solutions worldwide. Its medical devices are used for the treatment of surgical fixation of bone fractures for upper and lower extremities, as well as for the...

How the Company Makes Money

Medartis makes money primarily by selling osteosynthesis products used in surgical procedures. Its core revenue stream is the sale of implant systems (e.g., plates, screws and related fixation components) complemented by sales of surgical instrume...

Read more

Medartis makes money primarily by selling osteosynthesis products used in surgical procedures. Its core revenue stream is the sale of implant systems (e.g., plates, screws and related fixation components) complemented by sales of surgical instrume...

Medartis Holding AG Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	269.26M	224.83M	212.01M	182.82M	159.88M
Gross Profit	204.33M	178.68M	167.57M	135.39M	121.57M
EBITDA	45.72M	30.18M	24.69M	15.64M	26.10M
Net Income	8.35M	3.53M	619.00K	-5.78M	6.84M
Balance Sheet
Total Assets	559.92M	459.96M	349.53M	327.89M	298.18M
Cash, Cash Equivalents and Short-Term Investments	32.97M	138.69M	25.20M	20.60M	82.64M
Total Debt	157.72M	121.23M	27.39M	27.96M	24.07M
Total Liabilities	284.05M	190.31M	94.58M	90.11M	74.18M
Stockholders Equity	275.87M	269.65M	254.96M	237.78M	224.00M
Cash Flow
Free Cash Flow	9.34M	21.00M	5.05M	-22.72M	10.57M
Operating Cash Flow	34.82M	28.17M	19.96M	-3.93M	20.95M
Investing Cash Flow	-146.26M	-19.06M	-37.83M	-52.91M	-15.87M
Financing Cash Flow	6.83M	100.58M	23.21M	-3.90M	-4.78M

Medartis Holding AG Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 88.20
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:MED, the sentiment is Negative. The current price of 88.2 is above the 20-day moving average (MA) of 84.46, below the 50-day MA of 88.47, and above the 200-day MA of 84.40, indicating a bearish trend. The MACD of -2.34 indicates Positive momentum. The RSI at 40.63 is Neutral, neither overbought nor oversold. The STOCH value of 32.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:MED.

Medartis Holding AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BSLN	71 Outperform	CHF629.86M	16.63	―	―	58.51%	―
MOVE	69 Neutral	CHF2.96B	34.95	23.76%	0.45%	16.59%	65.76%
SOON	68 Neutral	CHF9.89B	17.11	―	2.14%	3.79%	-7.84%
SFZN	62 Neutral	CHF3.30B	19.36	15.79%	0.51%	0.77%	16.70%
TECN	55 Neutral	CHF1.62B	-14.70	4.57%	2.31%	-9.34%	-37.50%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MED	51 Neutral	CHF1.09B	131.13	―	―	7.29%	-112.70%

Medartis Holding AG Corporate Events